Lion Point Capital
Latest statistics and disclosures from Lion Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INSM, MIST, GERN, ARDX, FENC, and represent 50.59% of Lion Point Capital's stock portfolio.
- Added to shares of these 5 stocks: BLUE, BNTC, IRON, ARQT, SNDX.
- Started 1 new stock position in BLUE.
- Reduced shares in these 10 stocks: IWM (-$18M), MIRM, MIST, Marinus Pharmaceuticals, INSM, Bluebird Bio, BHVN, GERN, KNSA, BBIO.
- Sold out of its positions in GOOG, Bluebird Bio, IWM, Lumos Pharma, Marinus Pharmaceuticals, MSFT, MIRM.
- Lion Point Capital was a net seller of stock by $-25M.
- Lion Point Capital has $19M in assets under management (AUM), dropping by -57.47%.
- Central Index Key (CIK): 0001643354
Tip: Access up to 7 years of quarterly data
Positions held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Lion Point Capital
Lion Point Capital holds 19 positions in its portfolio as reported in the December 2024 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
|
|---|---|---|---|---|---|---|
| Insmed Com Par $.01 (INSM) | 13.3 | $2.5M | -29% | 37k | 69.04 |
|
| Milestone Pharmaceuticals (MIST) | 12.7 | $2.4M | -37% | 1.0M | 2.36 |
|
| Geron Corporation (GERN) | 9.3 | $1.8M | -20% | 500k | 3.54 |
|
| Ardelyx (ARDX) | 8.9 | $1.7M | -9% | 335k | 5.07 |
|
| Fennec Pharmaceuticals (FENC) | 6.5 | $1.2M | -8% | 196k | 6.32 |
|
| Bridgebio Pharma (BBIO) | 5.8 | $1.1M | -17% | 40k | 27.44 |
|
| Mineralys Therapeutics (MLYS) | 5.1 | $973k | 79k | 12.31 |
|
|
| Kiniksa Pharmaceuticals Ord Shs Cl A (KNSA) | 4.8 | $908k | -25% | 46k | 19.78 |
|
| Biohaven (BHVN) | 4.4 | $848k | -35% | 23k | 37.35 |
|
| Benitec Biopharma Com New (BNTC) | 4.1 | $783k | +58% | 62k | 12.63 |
|
| Syndax Pharmaceuticals (SNDX) | 3.8 | $727k | +19% | 55k | 13.22 |
|
| Jasper Therapeutics Com New (JSPR) | 3.6 | $684k | 32k | 21.38 |
|
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 3.5 | $673k | 64k | 10.51 |
|
|
| Disc Medicine (IRON) | 3.5 | $672k | +37% | 11k | 63.40 |
|
| Bluebird Bio Com New (BLUE) | 3.4 | $658k | NEW | 79k | 8.34 |
|
| Arcutis Biotherapeutics (ARQT) | 3.4 | $645k | +31% | 46k | 13.93 |
|
| Regenxbio Inc equity us cm (RGNX) | 2.3 | $446k | 58k | 7.73 |
|
|
| Seres Therapeutics (MCRB) | 1.5 | $283k | 341k | 0.83 |
|
|
| Spruce Biosciences (SPRB) | 0.2 | $32k | 75k | 0.42 |
|
Past Filings by Lion Point Capital
SEC 13F filings are viewable for Lion Point Capital going back to 2015
- Lion Point Capital 2024 Q4 filed Feb. 14, 2025
- Lion Point Capital 2024 Q3 filed Nov. 14, 2024
- Lion Point Capital 2024 Q2 filed Aug. 14, 2024
- Lion Point Capital 2024 Q1 filed May 15, 2024
- Lion Point Capital 2023 Q4 filed Feb. 14, 2024
- Lion Point Capital 2023 Q3 filed Nov. 14, 2023
- Lion Point Capital 2023 Q2 filed Aug. 14, 2023
- Lion Point Capital 2023 Q1 filed May 15, 2023
- Lion Point Capital 2022 Q4 filed Feb. 14, 2023
- Lion Point Capital 2022 Q3 filed Nov. 14, 2022
- Lion Point Capital 2022 Q2 filed Aug. 15, 2022
- Lion Point Capital 2022 Q1 filed May 16, 2022
- Lion Point Capital 2021 Q4 filed Feb. 14, 2022
- Lion Point Capital 2021 Q3 filed Nov. 15, 2021
- Lion Point Capital 2021 Q2 filed Aug. 16, 2021
- Lion Point Capital 2021 Q1 restated filed May 19, 2021